At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 184 enrolled
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
In Brief
A Phase 2 clinical trial evaluating Bimekizumab for Psoriatic Arthritis. Completed, enrolled 184 participants across 37 sites in 6 countries.
Detailed Summary
This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesCzechia, Germany, Hungary, Poland, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionOct 2020
TodayJul 2026
First PostedNov 20, 2017
Enrollment StartNov 22, 2017
Primary CompletionOct 29, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.6 years ago
Interventions
Bimekizumabdrug
Bimekizumab at a prespecified dose.